Introduction: What they say:
A study from the Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA shows that: “Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short.” This study was published in the 28 September 2016 issue of the journal “Scientific reports” by Prof. Li JD, Andrews CS and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anti-inflammatory therapy for upper respiratory tract inflammatory diseases: SMG7, a protein known to play a role in nonsense-mediated mRNA decay, increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene
Given that: (1) Pulmonary disease (PD) is a progressive degenerative disease of the lung, with debilitating consequences; (2) drugs that are currently used to treat inflammatory disease of the upper respiratory tract (URI) are ineffective, especially in aged patients; (3) molecular mechanisms involved in the development of URI inflammatory diseases is poorly understood; (4) Chronic obstructive inflammatory disease (COPD) is the third leading cause of death worldwide; (5) one-half billion people worldwide are affected by Asthma and COPD; (6) approx. 2. 5 lakhs of patients worldwide die of asthma every year; (7) microbes that cause these inflammatory diseases become resistant to conventional antibiotic therapy frequently; and (8) billions of dollars are being spent every year worldwide to treat these diseases, there is an urgent need to find: (i) a way to control abnormal levels of inflammatory mediators found in URI inflammatory disease patients; (ii) non-antibiotic therapeutics; (iii) a side-effect-free natural product-based drug; and (iv) a way to effectively treat and cure URI inflammatory disease.
What is known:
Prof. Li’s research team has recently shown that Resveratrol, by increasing the negative regulator of inflammation MyD88(s), it suppresses NTH-1-exacerbated inflammation.
From Research Findings to Therapeutic opportunity:
This study suggests, for the first time, that SMG7, by increasing the expression of its target gene, it may: (1) increase the expression of MKP/DUSP1; (2) decrease the phosphorylation and the activity of ERK1/2; (3) increase the expression of the negative regulator of inflammation MyD88-short. Thereby, it may inhibit: (1) respiratory pathogen NTHi-aggravated inflammation and its mediators such as IL-1β, IL-6, CCL-2 and GM-CSF; (2) lung inflammation; and (3) the progression of upper respiratory tract inflammatory diseases such as Asthma and Chronic obstructive inflammatory disease. Thus, pharmacological formulations encompassing “SMG7 activators” may be used to control inflammatory mediators in upper respiratory tract inflammatory diseases.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
To cite: Boominathan, L., Anti-inflammatory therapy for upper respiratory tract inflammatory diseases: SMG7, a protein known to play a role in nonsense-mediated mRNA decay, increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene, 14/November/2015, 10.10 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How SMG7 increases the expression of MyD88 (Short).
# Research cooperation